Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1069899/000141057822000100/pahc-20211231x10q.htm
May 2022
May 2022
February 2022
February 2022
January 2022
November 2021
November 2021
November 2021
August 2021
July 2021
Document and Entity Information - shares | 6 Months Ended | |
---|---|---|
Dec. 31, 2021 | Feb. 02, 2022 | |
Document Information [Line Items] | ||
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Transition Report | false | |
Document Period End Date | Dec. 31, 2021 | |
Entity File Number | 001-36410 | |
Entity Registrant Name | PHIBRO ANIMAL HEALTH CORP | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 13-1840497 | |
Entity Address, Address Line One | Glenpointe Centre East, 3rd Floor | |
Entity Address, Address Line Two | 300 Frank W. Burr Boulevard, Suite 21 | |
Entity Address, City or Town | Teaneck | |
Entity Address, State or Province | NJ | |
Entity Address, Postal Zip Code | 07666-6712 | |
City Area Code | 201 | |
Local Phone Number | 329-7300 | |
Title of 12(b) Security | Class A Common Stock, $0.0001 par value per share | |
Trading Symbol | PAHC | |
Security Exchange Name | NASDAQ | |
Entity Current Reporting Status | Yes | |
Entity Filer Category | Accelerated Filer | |
Entity Small Business | false | |
Entity Interactive Data Current | Yes | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Current Fiscal Year End Date | --06-30 | |
Document Fiscal Year Focus | 2022 | |
Document Fiscal Period Focus | Q2 | |
Entity Central Index Key | 0001069899 | |
Amendment Flag | false | |
Common stock-Class A | ||
Document Information [Line Items] | ||
Entity Common Stock, Shares Outstanding | 20,337,574 | |
Common stock-Class B | ||
Document Information [Line Items] | ||
Entity Common Stock, Shares Outstanding | 20,166,034 |
Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1069899/000141057822000100/pahc-20211231x10q.htm
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Phibro Animal Health Corp.
Phibro Animal Health Corp's Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:
Rating
Learn More![]()
The following are examples of how our Adjusted EBITDA measure is utilized: senior management receives a monthly analysis of our operating results that is prepared on an Adjusted EBITDA basis; our annual budgets are prepared on an Adjusted EBITDA basis; and other goal setting and performance measurements are prepared on an Adjusted EBITDA basis.
Accounts receivable provided $1.4 million of cash due to a higher proportion of domestic sales, which have a shorter customer collection period.
Mineral Nutrition Adjusted EBITDA increased $2.8 million with higher sales and related gross profit.
Operating income increased $2.4 million, driven by favorable gross profit.
SG&A expenses increased due to higher employee-related costs and strategic investments.
We consider acquisition-related activities and...Read more
Mineral Nutrition Adjusted EBITDA increased...Read more
Foreign currency (gains) losses, net...Read more
Animal Health Adjusted EBITDA increased...Read more
Operating income increased $1.3 million...Read more
Net sales of nutritional specialty...Read more
Net sales of MFAs and...Read more
As of December 31, 2021,...Read more
Important factors that could cause...Read more
Gross margin decreased 270 basis...Read more
Gross margin decreased 270 basis...Read more
Adjusted EBITDA is an alternative...Read more
The effective income tax rate,...Read more
Because of its non-standardized definition,...Read more
Selling, general and administrative expenses...Read more
Our processing aids used by...Read more
Our processing aids used by...Read more
Interest expense, net Interest expense,...Read more
Current period gains were driven...Read more
24 Interest expense, net of...Read more
Mineral Nutrition Net sales of...Read more
Despite the importance of this...Read more
Animal Health gross profit increased...Read more
We believe we will comply...Read more
The effective income tax rate...Read more
The effective income tax rate...Read more
22 Segment net sales and...Read more
* Calculation not meaningful 23...Read more
Comparison of six months ended...Read more
Income tax expense increased $1.7...Read more
Income tax expense increased $2.8...Read more
Performance Products Gross profit of...Read more
The effective income tax rate,...Read more
Animal Health, Mineral Nutrition and...Read more
Gross profit Gross profit of...Read more
Corporate expenses increased $1.2 million...Read more
Corporate expenses increased $0.2 million,...Read more
Animal Health Net sales of...Read more
Animal Health Net sales of...Read more
Mineral Nutrition Net sales of...Read more
Current period gains were driven...Read more
For discussion of new accounting...Read more
These statements may include words...Read more
Our Board of Directors declared...Read more
Net sales of vaccines increased...Read more
Net sales of vaccines increased...Read more
Interest expense decreased due to...Read more
While we believe that our...Read more
We have defined Adjusted EBITDA...Read more
Foreign currency (gains) losses, net...Read more
Net income Net income of...Read more
Performance Products Adjusted EBITDA decreased...Read more
This enables us to monitor...Read more
Animal Health SG&A increased $2.7...Read more
Inventory increases were primarily due...Read more
Liquidity and capital resources We...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-Q Quarterly Report
Material Contracts, Statements, Certifications & more
Phibro Animal Health Corp provided additional information to their SEC Filing as exhibits
Ticker: PAHC
CIK: 1069899
Form Type: 10-Q Quarterly Report
Accession Number: 0001410578-22-000100
Submitted to the SEC: Wed Feb 09 2022 4:11:07 PM EST
Accepted by the SEC: Wed Feb 09 2022
Period: Friday, December 31, 2021
Industry: Pharmaceutical Preparations